Tumor emergence is sensed by self-specific CD44hi memory Tregs that create a dominant tolerogenic environment for tumors in mice

Journal of Clinical Investigation

Volumn 119, Issue 9, 2009, Pages 2648-2662

  Darrasse Jèze, Guillaume ^a,b,c   Bergot, Anne Sophie ^a,b,c   Durgeau, Aurélie ^a,b,c   Billiard, Fabienne ^a,b,c   Salomon, Benoît L ^a,b,c   Cohen, José L ^a,b,c   Bellier, Bertrand ^a,b,c   Podsypanina, Katrina ^d   Klatzmann, David ^a,b,c,e  

^a SORBONNE UNIVERSITÉ   (France)

^b CNRS   (France)

^c Unit of Dermatology   (France)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; HERMES ANTIGEN; TUMOR MARKER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN DETECTION; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ARTICLE; CONTROLLED STUDY; EFFECTOR CELL; FEMALE; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOREGULATION; IMMUNOSURVEILLANCE; MEMORY CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS, CD44; ANTIGENS, POLYOMAVIRUS TRANSFORMING; BASE SEQUENCE; CELL LINE, TUMOR; DNA, COMPLEMENTARY; FEMALE; IMMUNOLOGIC MEMORY; MAMMARY NEOPLASMS, EXPERIMENTAL; MELANOMA, EXPERIMENTAL; MESOTHELIOMA; MICE; MICE, CONGENIC; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; MICE, TRANSGENIC; MODELS, IMMUNOLOGICAL; NEOPLASMS, EXPERIMENTAL; ONCOGENES; SELF TOLERANCE; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TIME FACTORS;

EID: 70349211735     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI36628     Document Type: Article

References (76)

1. Ochsenbein, A.F., et al. 1999. Immune surveillance against a solid tumor fails because of immunological ignorance. Proc. Natl. Acad. Sci. U. S. A. 96:2233-2238.
2. Burnet, M. 1957. Cancer: a biological approach. III. Viruses associated with neoplastic conditions. IV. Practical applications. Br. Med. J. 1:841-847.
3. Willimsky, G., and Blankenstein, T. 2005. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature. 437:141-146. (Pubitemid 41613441)
4. Yamaguchi, T., and Sakaguchi, S. 2005. Regulatory T cells in immune surveillance and treatment of cancer. Semin Cancer Biol. 16:115-123.
5. Shimizu, J., Yamazaki, S., and Sakaguchi, S. 1999. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163:5211-5218.
6. Curiel, T.J., et al. 2004. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10:942-949.
7. Chen, M.L., et al. 2005. Regulatory T cells suppress tumor-specific CD8 T cell cytotoxicity through TGF-beta signals in vivo. Proc. Natl. Acad. Sci. U. S. A. 102:419-424.
8. Ghiringhelli, F., et al. 2005. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J. Exp. Med. 202:919-929. (Pubitemid 41396892)
9. Wolf, D., et al. 2005. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin. Cancer Res. 11:8326-8331. (Pubitemid 41746944)
10. Sato, E., et al. 2005. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. U. S. A. 102:18538-18543. (Pubitemid 43011261)
11. Fontenot, J.D., Gavin, M.A., and Rudensky, A.Y. 2003. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 4:330-336.
12. Hori, S., Nomura, T., and Sakaguchi, S. 2003. Control of regulatory T cell development by the transcription factor Foxp3. Science. 299:1057-1061. (Pubitemid 36222930)
13. von Boehmer, H. 2005. Mechanisms of suppression by suppressor T cells. Nat. Immunol. 6:338-344.
14. Miyara, M., and Sakaguchi, S. 2007. Natural regulatory T cells: mechanisms of suppression. Trends Mol. Med. 13:108-116. (Pubitemid 46341958)
15. Sakaguchi, S. 2005. Naturally arising Foxp3- expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol. 6:345-352. (Pubitemid 41716771)
16. Belkaid, Y., and Rouse, B.T. 2005. Natural regulatory T cells in infectious disease. Nat. Immunol. 6:353-360. (Pubitemid 41716772)
17. Karlsson, M.R., Rugtveit, J., and Brandtzaeg, P. 2004. Allergen-responsive CD4+CD25+ regulatory T cells in children who have outgrown cow's milk allergy. J. Exp. Med. 199:1679-1688. (Pubitemid 38822001)
18. Cohen, J.L., Trenado, A., Vasey, D., Klatzmann, D., and Salomon, B.L. 2002. CD4(+)CD25(+) immunoregulatory T Cells: new therapeutics for graft-versus- host disease. J. Exp. Med. 196:401-406. (Pubitemid 34875668)
19. Berendt, M.J., and North, R.J. 1980. T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor. J. Exp. Med. 151:69-80.
20. Orentas, R.J., Kohler, M.E., and Johnson, B.D. 2006. Suppression of anti-cancer immunity by regulatory T cells: back to the future. Semin. Cancer Biol. 16:137-149.
21. Viguier, M., et al. 2004. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J. Immunol. 173:1444-1453. (Pubitemid 38924326)
22. Chaput, N., et al. 2007. Regulatory T cells prevent CD8 T cell maturation by inhibiting CD4 Th cells at tumor sites. J. Immunol. 179:4969-4978.
23. Onizuka, S., et al. 1999. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res. 59:3128-3133. (Pubitemid 29316012)
24. Golgher, D., Jones, E., Powrie, F., Elliott, T., and Gallimore, A. 2002. Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur. J. Immunol. 32:3267-3275. (Pubitemid 35414884)
25. Nishikawa, H., et al. 2005. Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatory T cells in wild-type hosts. Proc. Natl. Acad. Sci. U. S. A. 102:9253-9257. (Pubitemid 40923550)
26. Dannull, J., et al. 2005. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 115:3623-3633. (Pubitemid 43121851)
27. Sharma, M.D., et al. 2007. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3- dioxygenase. J. Clin. Invest. 117:2570-2582.
28. Nishikawa, H., et al. 2003. CD4+ CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses. Proc. Natl. Acad. Sci. U. S. A. 100:10902-10906. (Pubitemid 37140125)
29. Vence, L., et al. 2007. Circulating tumor antigen- specific regulatory T cells in patients with metastatic melanoma. Proc. Natl. Acad. Sci. U. S. A. 104:20884-20889.
30. Wang, H.Y., et al. 2004. Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity. 20:107-118.
31. Wang, H.Y., Peng, G., Guo, Z., Shevach, E.M., and Wang, R.F. 2005. Recognition of a new ARTC1 peptide ligand uniquely expressed in tumor cells by antigen-specific CD4+ regulatory T cells. J. Immunol. 174:2661-2670. (Pubitemid 40279680)
32. Beyer, M., and Schultze, J.L. 2006. Regulatory T cells in cancer. Blood. 108:804-811.
33. Fisson, S., et al. 2003. Continuous activation of autoreactive CD4+ CD25+ regulatory T cells in the steady state. J. Exp. Med. 198:737-746. (Pubitemid 37087773)
34. Setiady, Y.Y., et al. 2006. Physiologic self antigens rapidly capacitate autoimmune disease-specific polyclonal CD4+ CD25+ regulatory T cells. Blood. 107:1056-1062.
35. Huehn, J., et al. 2004. Developmental stage, phenotype, and migration distinguish naive- and effector/ memory-like CD4+ regulatory T cells. J. Exp. Med. 199:303-313. (Pubitemid 38252043)
36. Kim, J., Rasmussen, J., and Rudensky, A. 2006. Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat. Immunol. 8:191-197.
37. Bellier, B., Thomas-Vaslin, V., Saron, M.F., and Klatzmann, D. 2003. Turning immunological memory into amnesia by depletion of dividing T cells. Proc. Natl. Acad. Sci. U. S. A. 100:15017-15022. (Pubitemid 37518009)
38. Marzio, R., Mauel, J., and Betz-Corradin, S. 1999. CD69 and regulation of the immune function. Immunopharmacol. Immunotoxicol. 21:565-582.
39. Podsypanina, K., et al. 2008. Seeding and propagation of untransformed mouse mammary cells in the lung. Science. 321:1841-1844.
40. Madsen, L., et al. 1999. Mice lacking all conventional MHC class II genes. Proc. Natl. Acad. Sci. U. S. A. 96:10338-10343. (Pubitemid 29422559)
41. Lo, D., et al. 1992. Peripheral tolerance to an islet cell-specific hemagglutinin transgene affects both CD4+ and CD8+ T cells. Eur. J. Immunol. 22:1013-1022.
42. Van den Berg, C.L., et al. 1994. Pharmacokinetics of hydroxyurea in nude mice. Anticancer Drugs. 5:573-578.
43. Tough, D.F., and Sprent, J. 1994. Turnover of naive- and memory-phenotype T cells. J. Exp. Med. 179:1127-1135.
44. Fisson, S., et al. 2006. Therapeutic potential of self-antigen- specific CD4+ CD25+ regulatory T cells selected in vitro from a polyclonal repertoire. Eur. J. Immunol. 36:817-827.
45. Billiard, F., et al. 2006. Regulatory and effector T cell activation levels are prime determinants of in vivo immune regulation. J. Immunol. 177:2167-2174. (Pubitemid 44200975)
46. Julia, V., Rassoulzadegan, M., and Glaichenhaus, N. 1996. Resistance to Leishmania major induced by tolerance to a single antigen. Science. 274:421-423. (Pubitemid 26353355)
47. Kleinewietfeld, M., et al. 2005. CCR6 expression defines regulatory effector/memory-like cells within the CD25(+)CD4+ T-cell subset. Blood. 105:2877-2886. (Pubitemid 40446282)
48. Fritzsching, B., et al. 2006. Naive regulatory T cells: a novel subpopulation defined by resistance toward CD95L-mediated cell death. Blood. 108:3371-3378. (Pubitemid 44776876)
49. Seo, N., Hayakawa, S., Takigawa, M., and Tokura, Y. 2001. Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4(+) T-regulatory cells and systemic collapse of antitumour immunity. Immunology. 103:449-457. (Pubitemid 32744391)
50. Setoguchi, R., Hori, S., Takahashi, T., and Sakaguchi, S. 2005. Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization. J. Exp. Med. 201:723-735. (Pubitemid 40395118)
51. Granucci, F., et al. 2001. Inducible IL-2 production by dendritic cells revealed by global gene expression analysis. Nat. Immunol. 2:882-888. (Pubitemid 34906455)
52. Hanahan, D., and Weinberg, R.A. 2000. The hallmarks of cancer. Cell. 100:57-70.
53. Savage, P.A., et al. 2008. Recognition of a ubiquitous self antigen by prostate cancer-infiltrating CD8+ T lymphocytes. Science. 319:215-220.
54. Kasow, K.A., et al. 2004. Human CD4+CD25+ regulatory T cells share equally complex and comparable repertoires with CD4+CD25- counterparts. J. Immunol. 172:6123-6128.
55. Hsieh, C.S., Zheng, Y., Liang, Y., Fontenot, J.D., and Rudensky, A.Y. 2006. An intersection between the self-reactive regulatory and nonregulatory T cell receptor repertoires. Nat. Immunol. 7:401-410.
56. Shevach, E.M., et al. 2006. The lifestyle of naturally occurring CD4+ CD25+ Foxp3+ regulatory T cells. Immunol. Rev. 212:60-73.
57. Oven, I., et al. 2007. AIRE recruits P-TEFb for transcriptional elongation of target genes in medullary thymic epithelial cells. Mol. Cell. Biol. 27:8815-8823.
58. Aschenbrenner, K., et al. 2007. Selection of Foxp3+ regulatory T cells specific for self antigen expressed and presented by Aire+ medullary thymic epithelial cells. Nat. Immunol. 8:351-358. (Pubitemid 46745410)
59. Savage, P.A., Boniface, J.J., and Davis, M.M. 1999. A kinetic basis for T cell receptor repertoire selection during an immune response. Immunity. 10:485-492.
60. Veiga-Fernandes, H., Walter, U., Bourgeois, C., McLean, A., and Rocha, B. 2000. Response of naive and memory CD8+ T cells to antigen stimulation in vivo. Nat. Immunol. 1:47-53.
61. Klein, L., Khazaie, K., and von Boehmer, H. 2003. In vivo dynamics of antigen-specific regulatory T cells not predicted from behavior in vitro. Proc. Natl. Acad. Sci. U. S. A. 100:8886-8891. (Pubitemid 36899193)
62. Zhou, G., Drake, C.G., and Levitsky, H.I. 2006. Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood. 107:628-636. (Pubitemid 43076387)
63. Qin, Z., and Blankenstein, T. 2000. CD4+ T cell- mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFNgamma receptor expression by nonhematopoietic cells. Immunity. 12:677-686.
64. Casares, N., et al. 2003. CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-γ-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J. Immunol. 171:5931-5939. (Pubitemid 37467211)
65. Yang, J., et al. 2007. Allograft rejection mediated by memory T cells is resistant to regulation. Proc. Natl. Acad. Sci. U. S. A. 104:19954-19959.
66. Nishikawa, H., Jager, E., Ritter, G., Old, L.J., and Gnjatic, S. 2005. CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients. Blood. 106:1008-1011.
67. Cederbom, L., Hall, H., and Ivars, F. 2000. CD4+CD25+ regulatory T cells down-regulate costimulatory molecules on antigen-presenting cells. Eur. J. Immunol. 30:1538-1543. (Pubitemid 30342794)
68. Dubey, C., Croft, M., and Swain, S.L. 1996. Naive and effector CD4 T cells differ in their requirements for T cell receptor versus costimulatory signals. J. Immunol. 157:3280-3289. (Pubitemid 126449137)
69. Korn, T., et al. 2007. Myelin-specific regulatory T cells accumulate in the CNS but fail to control autoimmune inflammation. Nat. Med. 13:423-431. (Pubitemid 46559831)
70. Galon, J., et al. 2006. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 313:1960-1964. (Pubitemid 44498003)
71. Pages, F., et al. 2005. Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med. 353:2654-2666. (Pubitemid 41817714)
72. Munn, D.H., and Mellor, A.L. 2007. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J. Clin. Invest. 117:1147-1154.
73. Davis, M.R., Manning, L.S., Whitaker, D., Garlepp, M.J., and Robinson, B.W. 1992. Establishment of a murine model of malignant mesothelioma. Int. J. Cancer. 52:881-886. (Pubitemid 23009503)
74. Marzo, A.L., et al. 1999. Tumor antigens are constitutively presented in the draining lymph nodes. J. Immunol. 162:5838-5845.
75. Gunther, E.J., et al. 2002. A novel doxycycline-inducible system for the transgenic analysis of mammary gland biology. FASEB J. 16:283-292.
76. Darrasse-Jeze, G., Klatzmann, D., Charlotte, F., Salomon, B.L., and Cohen, J.L. 2006. CD4+CD25+ regulatory/suppressor T cells prevent allogeneic fetus rejection in mice. Immunol. Lett. 102:106-109.